technetium-tc-99m-exametazime and Renal-Insufficiency

Combined pancreatic-renal transplants promise the restoration of physiologic control of serum glucose and normal renal function. As pancreatic transplantation becomes more common, there is an increased need for rapid, noninvasive evaluation of vascular graft patency and function. Pancreatic transplants share the renal transplant's complications of ischemia at harvest but are at greater risk. Tc-99m HMPAO is a lipophilic complex that clears rapidly from the blood after intravenous injection, and tissue accumulation is proportional to regional perfusion. Using Tc-99m HMPAO to monitor the vascular competency has the advantage of a high count rate during dynamic scintigrams but, in contrast to Tc-99m DTPA, has excellent delayed static images. Four patients who received combined cadaveric pancreatic-renal transplants and had a total of eight Tc-99m HMPAO scintigraphic examinations were reviewed.

Topics: Adult; Cadaver; Diabetes Mellitus, Type 1; Female; Graft Survival; Humans; Kidney Transplantation; Male; Organotechnetium Compounds; Oximes; Pancreas Transplantation; Radionuclide Imaging; Renal Insufficiency; Technetium Tc 99m Exametazime; Vascular Patency